Back To: Home


 
Name:
Company:
Email:
 
 




 

Eisai and FORMA Therapeutics enter into broad drug discovery collaboration
January 2011
SHARING OPTIONS:

WOODCLIFF LAKE, N.J.Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., and FORMA Therapeutics have signed a strategic drug discovery collaboration. Under the terms of the agreement, Eisai will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai's pipeline. In addition, Eisai has an option for technology transfer of FORMA's cell-based screening platform. FORMA will receive upfront payments and committed funding of $20 million over three years and is eligible to receive additional milestones plus royalties on future products that Eisai may commercialize as a result of this collaboration. Further details were not disclosed.    

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2015 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.